Celldex Therapeutics (CLDX)
(Delayed Data from NSDQ)
$25.92 USD
+1.46 (5.97%)
Updated Sep 18, 2025 04:00 PM ET
After-Market: $25.92 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, Celldex Therapeutics, Inc. has a market cap of $1.62B, which represents its share price of $24.46 multiplied by its outstanding shares number of 66.41M. As a small-cap company, CLDX's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
CLDX 25.92 +1.46(5.97%)
Will CLDX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CLDX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CLDX
Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates
scPharmaceuticals (SCPH) Soars 8.8%: Is Further Upside Left in the Stock?
CLDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Xenon Pharmaceuticals (XENE) Up 8.7% Since Last Earnings Report: Can It Continue?
Celldex Therapeutics (CLDX) Reports Q1 Loss, Lags Revenue Estimates
Cytokinetics (CYTK) Moves 5.4% Higher: Will This Strength Last?
Other News for CLDX
Is CLDX setting up for a drop? Shooting Star Candlestick shows up after sliding 0.49%
Celldex (CLDX) Reports Promising Phase 2 Results for Barzolvolimab in CSU
Celldex’s barzo shows strong efficacy in CSU patients, says H.C. Wainwright
Celldex’s Barzolvolimab Shows Promising Efficacy in Treating Chronic Spontaneous Urticaria Across Patient Subgroups
Celldex's barzo shows strong efficacy in CSU patients, says H.C. Wainwright